LR-90 is primarily investigated for its potential therapeutic applications in the treatment of diabetes and its complications. It is known to act as an advanced glycation end-product (AGE) inhibitor, which helps in reducing the harmful effects of glycation on tissues and organs. This makes it a promising candidate for managing diabetic nephropathy, a condition where kidney function is impaired due to diabetes. Additionally, LR-90 has shown potential in mitigating oxidative stress and inflammation, which are common in diabetic patients. Its ability to protect against vascular damage and improve endothelial function further supports its use in addressing cardiovascular complications associated with diabetes. Research is ongoing to explore its efficacy and safety in clinical settings.